CVRx Inc (CVRX)vsEli Lilly and Company (LLY)
CVRX
CVRx Inc
$2.88
+0.70%
HEALTHCARE · Cap: $76.73M
LLY
Eli Lilly and Company
$1,115.70
-0.65%
HEALTHCARE · Cap: $994.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 130099% more annual revenue ($79.67B vs $61.19M). LLY leads profitability with a 33.5% profit margin vs -84.9%. LLY earns a higher WallStSmart Score of 76/100 (B+).
CVRX
Avoid31
out of 100
Grade: F
LLY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.8%
Fair Value
$20.80
Current Price
$2.88
$17.92 discount
Intrinsic value data unavailable for LLY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
15.6% revenue growth
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -180.9% — below average capital efficiency
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : CVRX
The strongest argument for CVRX centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bear Case : CVRX
The primary concerns for CVRX are EPS Growth, Market Cap, Piotroski F-Score. Debt-to-equity of 2.98 is elevated, increasing financial risk.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Key Dynamics to Monitor
CVRX carries more volatility with a beta of 0.76 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
LLY scores higher overall (76/100 vs 31/100), backed by strong 33.5% margins and 47.7% revenue growth. CVRX offers better value entry with a 70.8% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVRx Inc
HEALTHCARE · MEDICAL DEVICES · USA
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?